![Biohaven Announces Exclusive License With Catalent For Zydis® Orally Dissolving Tablet With Small Molecule CGRP Receptor Antagonists Biohaven Announces Exclusive License With Catalent For Zydis® Orally Dissolving Tablet With Small Molecule CGRP Receptor Antagonists](https://mma.prnewswire.com/media/644289/image001.jpg)
Biohaven Announces Exclusive License With Catalent For Zydis® Orally Dissolving Tablet With Small Molecule CGRP Receptor Antagonists
![Biohaven Announces Exclusive License with Catalent for Zydis | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology Biohaven Announces Exclusive License with Catalent for Zydis | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology](https://media.americanpharmaceuticalreview.com/m/28/article/347346-333x250.jpg)
Biohaven Announces Exclusive License with Catalent for Zydis | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology
![A sequential dosing approach for the Zydis® freeze dried orally disintegrating tablet, by L.Grother, L. Garrett, R. McLaughlin A sequential dosing approach for the Zydis® freeze dried orally disintegrating tablet, by L.Grother, L. Garrett, R. McLaughlin](http://www.biopharma-asia.com/wp-content/uploads/2014/09/f5.jpg)
A sequential dosing approach for the Zydis® freeze dried orally disintegrating tablet, by L.Grother, L. Garrett, R. McLaughlin
![WHITEPAPER - Infographic-Zydis® Orally Disintegrating Tablet (ODT) vs. Standard Tablets (ST) - Drug Development and Delivery WHITEPAPER - Infographic-Zydis® Orally Disintegrating Tablet (ODT) vs. Standard Tablets (ST) - Drug Development and Delivery](https://d2akihtr51eb46.cloudfront.net/wp-content/uploads/2023/01/Infographic-Zydis%C2%AE-Orally-Disintegrating-Tablet-ODT-vs.-Standard-Tablets-ST-204x300.jpg)